This record was last updated April 19, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Diffuse glioms are primary brain tumors characterized by infiltrative growth and high heterogeneity, which render the disease mostly incurable. Advances in genetic analysis revealed that molecular and epigenetic alterations predict patients´s overall survival and clinical outcome. However, glioma tumorigenicity is not exclusively caused by its genetic alterations. The crosstalk between tumor cells and the surrounding microenvironment plays a crucial role in modulating glioma growth and aggressiveness. In this sense, to understand the tumor microenvironment would elucidate potential treatment alternatives. The focus will be to evaluate myeloid cells and cytokines levels.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-06-14; most recent amendment 2024-04-17.
Status change: Recruiting → Active, Not Recruiting2020-07-28